Labcorp on US$150 Million Acquisition Of Myriad Genetics’ Vectra Testing Business

Hogan Lovells advised Labcorp on the deal.

Labcorp acquired select operating assets and intellectual property from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis assay, in a transaction valued at US$150 million.

Rheumatoid arthritis, an autoimmune disorder and one of the most common forms of arthritis, causes painful inflammation and tissue damage in the knees, wrists, and other joints. Vectra is a non-invasive, blood-based test that analyzes 12 biomarkers to measure rheumatoid arthritis activity, creating an easy-to-understand score indicating severity and how well current treatments are working. It also can predict potential  joint damage, enabling targeted treatment and adjust existing treatments to better manage symptoms.

The transaction is expected to close by the end of Q3 2021. The Hogan Lovells team was led by New York-based M&A partner Michael Silver (Picture) and Washington D.C.-based M&A partner Allen Hicks. They were supported by senior associate Matt Bowles, and associates Nick Eckstein and Monica Pyles.

Involved fees earner: Matthew Bowles – Hogan Lovells; Nicholas Eckstein – Hogan Lovells; Allen Hicks – Hogan Lovells; Monica Pyles – Hogan Lovells; Michael Silver – Hogan Lovells;

Law Firms: Hogan Lovells;

Clients: Labcorp;

Author: Martina Bellini